CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

Table 1

Drugs targeting CD47-SIRPα axis that are currently being tested in humans.

Drug name	Company	Mechanism of action	Clinical trial ID	Target malignancy	Combined with	Clinical phase	Status (June 2020)
Magrolimab (Hu5F-G4)	Gilead Sciences (previously, Forty-Seven Inc.)	Anti-CD47 mAb	NCT02953509	Relapsing NHL	Rituximab	Phase 1 & 2	Recruiting
			NCT03869190	Urothelial carcinoma	Several	Phase 1 & 2	Recruiting
			NCT03248479	AML & MDS	Azacitidine	Phase 1	Recruiting
BI735063	OSE Immunotherapeutics/Boehringer Ingelheim	Anti-SIRPα mAb	NCT03990233	Advanced solid tumors	Monotherapy or PD-1 inhibitor (BI 754091)	Phase 1	Recruiting
CC95251	Celgene	Anti- SIRPα mAb	NCT03783403	Advanced solid & hematologic cancers	Rituximab or Cetuximab	Phase 1	Recruiting
IBI188	Innovent Biologics (Suzhou) Co. Ltd.	Anti-CD47 mAb	NCT03763149	Advanced malignant tumors and lymphomas	Monotherapy	Phase 1	Recruiting
			NCT03717103	Advanced malignancies	Rituximab	Phase 1	Recruiting
TTI621	Trillium Therapeutics Inc.	SIRPαFc-soluble recombinant fusion protein	NCT02663518	Hematologic malignancies and selected solid tumors	Rituximab or Nivolumab	Phase 1	Recruiting
TT622	Trillium Therapeutics Inc.	SIRPα-IgG4 Fc-soluble recombinant fusion protein	NCT03530683	Refractory lymphoma and myeloma	Monotherapy, rituximab, PD-1 inhibitor, or proteasome inhibitor	Phase 1	Recruiting
AO176	Arch Oncology	Anti-CD47 mAb	NCT03834948	Multiple solid malignancies	Monotherapy	Phase 1	Recruiting
ALX148	ALX Oncology Inc.	SIRPα soluble recombinant fusion protein	NCT03013218	Advanced Solid & Hematologic Cancers	Monotherapy, Pembrolizumab, Trastuzumab, rituximab, Ramucirumab+ Paclitaxel, 5-FU+ Cisplatin	Phase 1	Recruiting